Antineoplastic Agents TRIZ Cases
- Dihydroorotate Dehydrogenase Inhibitors for Glioblastoma Treatment
DHODH inhibitors block pyrimidine synthesis to overcome hypoxic protection and extend survival in glioblastoma.
- Nitrogen Mustard Prodrugs for Hypoxic Tumour Targeting
Haloalkanesulfonate derivatives resolve aqueous solubility and off-target activation contradictions in hypoxic tumour regions.
- Estradiol Etherification via Dimethyl Carbonate Solvent
Dimethyl carbonate replaces ethanolic potassium hydroxide to cut etherification time below 20 hours and raise yields above 70 percent.
- FGFR4 Selective Inhibitor Combination Therapy for Liver Cancer
Formula I FGFR4 inhibitors paired with palbociclib or lenvatinib resolve off-target toxicity while maintaining therapeutic efficacy in liver cancer treatment.
- Myt1 Kinase Inhibitors for CCNE1 Amplified Cancer Treatment
Myt1 inhibitors induce cell death in cancers with CCNE1 amplification or FBXW7 mutations by selectively binding the kinase active site.
- Coffee-Based Composition Inhibiting Cancer Metastasis via VCAM1 Modulation
A coffee-based pharmaceutical composition inhibits cancer metastasis and growth by targeting VCAM1 protein expression.
- EED Inhibitor Combination for Cancer Treatment
Merges EED inhibitors with targeted agents to overcome drug resistance and reduce toxicity in cancer therapy.
- Akt Inhibitor Combination Therapy for Cancer Treatment
Combining Akt activation inhibitors with CHK1, HDAC, or PI3K blockers creates synergistic pharmaceutical compositions.
- Selenopsammaplin A Inhibits DOT1L to Suppress Breast Cancer Metastasis
Selenopsammaplin A overcomes resistance in triple-negative breast cancer by targeting DOT1L, extending remission duration beyond conventional agents.
- Sorafenib Regorafenib Use in Myeloproliferative Neoplasms
Sorafenib and regorafenib inhibit tumor cell proliferation and induce apoptosis in drug-resistant myeloproliferative neoplasms.
- Ephrin Type-A Receptor 7 Antibodies for Bladder Cancer Diagnosis
Antibodies targeting Ephrin type-A receptor 7 provide non-invasive bladder cancer monitoring while reducing systemic toxicity.
- Scaffold-Kinase Interaction Blockade for Cancer Treatment
IQGAP1 WW peptides disrupt scaffold-kinase binding to bypass resistance mechanisms in RAS-driven cancers.
- Propargyl-Functionalized Macrocycles Prevent Aggregation
Propargyl-functionalized macrocycles prevent self-association, solving low yield and purification challenges in synthesis.
- Mitofusin Activator MASM7 HR2 Domain Binding
MASM7 targets the HR2 domain of mitofusin 2 to resolve unclear mechanisms and off-target effects while increasing oxygen consumption.
- Hydroxyl Xanthone Derivatives Inhibit Na/K-ATPase Pumping
Hydroxyl xanthone derivatives reduce sodium and ATP affinities on the enzyme to inhibit ion pumping function.
- Terpenic Coumarin Derivatives for Selective Cancer Cell Targeting
Terpenic coumarin derivatives modify molecular structure to selectively inhibit cancer cell proliferation while sparing healthy tissue.
- Combination Therapy for T-ALL Reversing Notch Inhibitor Resistance
Combination therapy targets cancer cells with Notch pathway mutations using bromodomain and Bcl-2 inhibitors.